Tags: Drug.
Iniparib (previously BSI 201) (4-iodo-3-nitrobenzamide) was a drug candidate for cancer treatment. It was originally believed to act as an irreversible inhibitor of PARP1 (hence a PARP inhibitor) and possibly other enzymes through covalent modification but its effects against PARP were later disproven. It underwent clinical trials for treatment of some types of breast cancer but was discontinued after disappointing Phase III clinical trials.
